Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12445146 | 0.81 | LMNA (0.43) | — | |
| SCHEMBL12445148 | 0.73 | CYP11B2 (0.46) | CYP11B2HRH3SLC9A3CCNCCDK8 | |
| SCHEMBL1966124 | 0.70 | CMA1 (0.41) | — | |
| SCHEMBL8118010 | 0.69 | GAA (0.39) | PARP1 | |
| SCHEMBL12444827 | 0.69 | TNKS (0.34) | SLC9A3CCNCCDK8TNKSIDH1 | |
| SCHEMBL5486378 | 0.69 | PRKAG1 (0.40) | SLC9A3CCNCCDK8TNKSIDH1 | |
| SCHEMBL11595049 | 0.69 | IDH1 (0.40) | TNKSIDH1EGLN2 | |
| SCHEMBL153211 | 0.68 | AHR (0.45) | PARP1 | |
| SCHEMBL20575529 | 0.68 | BCL2 (0.36) | CCNCCDK8TNKSIDH1EGLN2 | |
| SCHEMBL1455890 | 0.67 | BCL2 (0.48) | TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED | 2013-02-28 | — | — | US | disclosed |
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED | 2013-02-28 | — | — | US | disclosed |
| WO-2011098776-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | HTR1B, HTR5A, HTR1A | CYP11B2 583/4885RIPK1 2940/4885HRH3 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.